Serina Therapeutics Files 8-K with Corporate Updates

TL;DR

Serina Therapeutics filed an 8-K on 8/22 for events on 8/18, including corporate changes and financials.

AI Summary

Serina Therapeutics, Inc. filed an 8-K on August 22, 2025, reporting events as of August 18, 2025. The filing includes amendments to its articles of incorporation or bylaws and financial statements and exhibits. The company, formerly known as AgeX Therapeutics, Inc. until June 6, 2017, is located in Huntsville, Alabama.

Why It Matters

This 8-K filing indicates corporate actions and financial reporting by Serina Therapeutics, Inc., which could impact investors' understanding of the company's current status and future direction.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant negative news or events.

Key Players & Entities

• Serina Therapeutics, Inc. (company) — Registrant
• August 18, 2025 (date) — Earliest event date
• August 22, 2025 (date) — Report date
• AgeX Therapeutics, Inc. (company) — Former company name
• June 6, 2017 (date) — Date of name change
• Huntsville, Alabama (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share SE R NYSE American Indicate

Filing Documents

• ser-20250818.htm (8-K) — 24KB
• serinade-secondamendmentto.htm (EX-3.1) — 40KB
• 0001708599-25-000101.txt ( ) — 194KB
• ser-20250818.xsd (EX-101.SCH) — 2KB
• ser-20250818_lab.xml (EX-101.LAB) — 23KB
• ser-20250818_pre.xml (EX-101.PRE) — 13KB
• ser-20250818_htm.xml (XML) — 3KB

03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On August 18, 2025, the Board of Directors of Serina Therapeutics, Inc. (the "Company") amended the Company's Amended and Restated Bylaws (the "Bylaws Amendment") to (i) provide a number of safe harbor procedures for acts or transactions involving the Company in which one or more directors or officers as well as controlling stockholders and members of control groups have interests or relationships that might render them interested or not independent with respect to the act or transaction and (ii) supplement the forum selection clause in Section 9.2 of the Company's Amended and Restated Certificate of Incorporation to expand the coverage of the forum selection clause to include claims of stockholders, when acting in their capacity as stockholders or in the right of the corporation, if such claims relate to the business of the corporation, the conduct of its affairs, or the rights or powers of the corporation or its stockholders, directors or officers. The foregoing description of the Bylaws Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Bylaws Amendment attached hereto as Exhibit 3.1 and incorporated herein by reference.

01 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 3.1 Second Amendment to Amended and Restated Bylaws of Serina Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: August 22, 2025 By: /s/ Gregory S. Curhan Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR